Pterygium Excision with Conjunctival Limbal Allograft (CLAL) — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>A <strong>pterygium</strong> (plural: pterygia) is a non-cancerous, fibrovascular growth of the conjunctiva — the transparent mucous membrane covering the white of the eye — that encroaches onto the clear cornea. The word derives from the Greek <em>pterygion</em>, meaning "wing," describing its characteristic wing-shaped appearance. Pterygia typically arise from the nasal aspect of the eye and may extend toward the visual axis. Prolonged exposure to ultraviolet (UV) radiation, wind, dust, and dry conditions are the primary environmental triggers; the condition is therefore far more prevalent in tropical and subtropical regions, and among outdoor workers.</p><p>Surgical removal — <strong>pterygium excision</strong> — is the definitive treatment when the pterygium causes symptoms or threatens vision. The critical challenge with pterygium surgery is not the excision itself but the prevention of recurrence: bare sclera excision (removing the pterygium and leaving the underlying sclera exposed) carries a recurrence rate of 40–80%, often with the regrowth being more aggressive than the original lesion. To address this, modern techniques use a tissue graft to cover the excision site.</p><p><strong>Conjunctival Limbal Allograft (CLAL)</strong> is a technique in which conjunctival tissue including <em>limbal stem cells</em> is harvested from a donor (either a cadaveric donor or a living related donor) and transplanted to the excision site in the recipient. The limbus is the anatomical border between the clear cornea and the white sclera; limbal stem cells reside here and are responsible for continuously replenishing the corneal epithelium. By transplanting these cells, CLAL restores the normal epithelial barrier at the corneoscleral junction, substantially reducing recurrence rates to approximately 3–10%.</p><p>CLAL is particularly indicated for cases of <strong>recurrent pterygium</strong> (where the patient's own conjunctiva from the same eye has already been used or is scarred), bilateral pterygia (where the patient cannot afford to sacrifice conjunctiva from either eye), or severe cases where a large defect requires reconstruction beyond what a conjunctival autograft from the same eye can provide. Because the graft comes from a donor rather than the patient, immunosuppressive eye drops are required post-operatively to prevent graft rejection.</p>

<p>Pterygium excision with CLAL is performed for pterygia that cause one or more of the following clinical problems:</p><h3>Visual Impairment</h3><p>A pterygium growing toward or across the visual axis (pupillary area) can directly obstruct vision. Even before reaching the visual axis, induced <strong>irregular corneal astigmatism</strong> is common, as the fibrovascular tissue mechanically distorts the corneal curvature. Studies have documented significant reductions in best-corrected visual acuity (BCVA) and increases in higher-order aberrations in eyes with moderate to large pterygia. Surgery is typically recommended once astigmatism exceeds 1.5–2 dioptres or the leading edge of the pterygium is within 2–3 mm of the visual axis.</p><h3>Chronic Ocular Surface Symptoms</h3><p>Pterygia frequently cause persistent redness, foreign body sensation, dryness, tearing, and photophobia. These symptoms arise from abnormal tear film dynamics over the raised fibrovascular tissue, chronic inflammation, and impaired blinking over the elevated growth. In patients with significant daily discomfort that fails to respond to lubricant eye drops, UV-protective eyewear, and topical anti-inflammatory medications, surgical removal is appropriate.</p><h3>Recurrent Pterygium</h3><p>Recurrent pterygia following previous surgery are more vascularised, more adherent to the underlying tissue, and more aggressive than primary lesions. They are also associated with symblepharon (adhesion between the eyelid and globe) in severe cases. The conjunctiva adjacent to a recurrent pterygium is often scarred or inflamed, making autograft harvesting from the same eye difficult or impossible. CLAL from a cadaveric donor is the preferred reconstructive option in these cases.</p><h3>Limbal Stem Cell Deficiency (Partial)</h3><p>A large pterygium can destroy a significant portion of the limbal stem cell population at the nasal limbus. CLAL not only closes the surgical defect but actively replaces lost limbal stem cells, restoring the normal corneal epithelial renewal mechanism and reducing the long-term risk of conjunctivalisation of the cornea (an abnormal process where conjunctival epithelium grows over the corneal surface, causing chronic inflammation and vision loss).</p><h3>Pre-Cataract or Pre-Refractive Surgery</h3><p>A pterygium must be excised before cataract extraction or refractive surgery (LASIK, PRK) because it distorts corneal topography, makes accurate biometry for intraocular lens power calculation unreliable, and the surgical field must be clear. Ophthalmologists typically recommend waiting 3–6 months after pterygium removal before proceeding with refractive procedures to allow corneal shape to stabilise.</p>

<p>Not all pterygia require surgery, and patient selection for CLAL specifically requires careful consideration. The decision to operate — and to choose CLAL over other graft options — depends on clinical, anatomical, and patient-specific factors.</p><h3>Indications for Surgery (General)</h3><p>Surgery is indicated when the pterygium: (1) encroaches within 2–3 mm of the corneal light reflex (centre of the pupil); (2) induces astigmatism of more than 1.5 dioptres; (3) causes vision loss not correctable with spectacles; (4) causes significant, persistent ocular surface symptoms unrelieved by conservative measures; (5) has grown noticeably over a 6–12 month observation period; or (6) interferes with eyelid movement or contact lens wear. Purely cosmetic removal of small, stable, asymptomatic pterygia is generally not recommended, as surgical complications may outweigh the benefit.</p><h3>Specific Indications for CLAL (Over Autograft)</h3><p>CLAL is preferred over conjunctival autograft (where tissue is taken from the patient's own superior conjunctiva) in the following situations: <strong>Recurrent pterygium:</strong> Especially after a prior conjunctival autograft, where the autograft harvest site has been used. <strong>Bilateral pterygium:</strong> If both eyes require surgery simultaneously or have both already had surgery, insufficient donor conjunctiva remains in either eye. <strong>Large excision defects:</strong> When the defect after excision is too large to cover with an autograft from the superior conjunctiva. <strong>Prior glaucoma filtration surgery:</strong> When the superior conjunctiva must be preserved for potential future trabeculectomy. <strong>Scarred or previously inflamed conjunctiva:</strong> Where the available autograft tissue is of poor quality.</p><h3>Contraindications and Cautions</h3><p>CLAL is relatively contraindicated in patients who cannot reliably use immunosuppressive eye drops post-operatively, those with systemic immunodeficiency, severe ocular surface disease unrelated to the pterygium, or active ocular infection. Patients with small, stable, asymptomatic nasal pterygia that do not threaten vision are best managed with observation, UV-protective sunglasses, and lubricant eye drops rather than surgery.</p><h3>Pre-Operative Assessment</h3><p>Before surgery, the ophthalmologist will assess: visual acuity and refraction; corneal topography (to quantify pterygium-induced astigmatism); slit-lamp examination to characterise the pterygium (head, neck, body dimensions; degree of vascularity; presence of symblepharon); and overall ocular surface health. Pre-operative corneal topography serves as a baseline against which post-operative recovery is assessed.</p>

<p>Pterygium surgery has evolved significantly from simple excision, and the choice of technique fundamentally determines the risk of recurrence. The major approaches are described below:</p><h3>Bare Sclera Excision (Historical)</h3><p>The earliest technique: the pterygium is excised and the underlying bare sclera is left to heal by secondary intention. Recurrence rates are very high (40–80%), and this technique is now considered substandard of care for primary pterygium. It remains practiced in some resource-limited settings, sometimes combined with adjuvant mitomycin-C (MMC) to reduce recurrence — but MMC alone does not provide the low recurrence rates achieved with graft coverage.</p><h3>Conjunctival Autograft (CAG) — The Current Standard for Primary Pterygium</h3><p>A free graft of conjunctival tissue is harvested from the superior bulbar conjunctiva of the <em>same</em> eye (or occasionally the fellow eye) and sutured or glued (using fibrin glue — TISSEEL) over the excision site. CAG achieves recurrence rates of 2–10% in most series and is the gold standard for primary pterygium surgery. Tissue adhesive fixation (fibrin glue) has replaced sutures in many centres, reducing operating time and post-operative discomfort. CAG requires adequate superior conjunctiva and is not suitable when this has been used previously.</p><h3>Conjunctival Limbal Allograft (CLAL)</h3><p>In CLAL, a conjunctival graft that includes the limbal zone (and therefore limbal stem cells) is harvested from a donor — typically a HLA-matched or partially matched cadaveric eye bank donor or a living HLA-compatible relative. The graft is sutured or glued into the excision defect with the limbal edge oriented toward the cornea. The limbal stem cells in the graft repopulate the corneoscleral junction and provide a sustained barrier against recurrence. Reported recurrence rates with CLAL range from 3–10%, comparable to CAG. The key additional consideration is the requirement for post-operative immunosuppression (typically topical cyclosporine A and/or corticosteroid drops for several months) to prevent allograft rejection.</p><h3>Amniotic Membrane Transplant (AMT)</h3><p>Cryopreserved or lyophilised human amniotic membrane can be used to cover the excision site. AMT provides anti-inflammatory, anti-fibrotic, and pro-healing properties and reduces scarring. Recurrence rates with AMT alone are higher than with CAG or CLAL (approximately 10–20%), but it is valuable when conjunctival tissue is scarce or in cases of severe ocular surface disease where AMT's unique properties are beneficial. AMT is frequently combined with CAG for very large defects.</p><h3>Adjuvant Mitomycin-C (MMC)</h3><p>MMC is an alkylating agent that inhibits fibroblast proliferation. It is applied to the bare sclera at the time of excision (intraoperative application, 0.02–0.04% for 1–3 minutes, then washed off) to reduce the fibrovascular response that leads to recurrence. When combined with a graft, MMC provides additional anti-recurrence benefit but carries risks of scleral melting and delayed wound healing if used at higher concentrations. Its routine use with CLAL remains debated; most centres reserve intraoperative MMC for recurrent pterygia with high recurrence risk.</p>

<p>When performed by an experienced corneal surgeon, pterygium excision with CLAL offers several meaningful clinical benefits, especially in the context of recurrent or complex pterygia:</p><h3>Low Recurrence Rate</h3><p>CLAL achieves recurrence rates comparable to conjunctival autograft (3–10%), dramatically superior to bare sclera excision alone (40–80%). For patients who have already had one or more recurrences, CLAL represents the best available surgical option to definitively address the pterygium with low likelihood of further recurrence.</p><h3>Restoration of Limbal Stem Cell Population</h3><p>Unlike AMT or bare sclera techniques, CLAL restores the pool of limbal epithelial stem cells at the corneoscleral junction. This has long-term benefits for corneal surface health, reducing the risk of conjunctivalisation (ingrowth of conjunctival epithelium onto the cornea), chronic epithelial instability, and recurrent erosions.</p><h3>Improvement in Visual Acuity and Corneal Clarity</h3><p>Removal of the fibrovascular tissue from the corneal surface allows the cornea to gradually reshape. Most patients experience significant reduction in pterygium-induced astigmatism over 3–6 months post-operatively, with corresponding improvement in visual acuity and quality of vision. Corneal topography typically normalises substantially within 3 months, after which definitive spectacle or contact lens prescription can be made.</p><h3>Relief of Chronic Ocular Surface Symptoms</h3><p>The majority of patients (over 85% in published series) report significant improvement in redness, foreign body sensation, dryness, and photophobia following pterygium excision. The graft creates a smooth, vascularised conjunctival surface that restores normal tear film dynamics over the operated area.</p><h3>Cosmetic Improvement</h3><p>A healthy, white conjunctival surface replaces the reddened fibrovascular growth. Many patients with cosmetically distressing pterygia — particularly those involving the visible interpalpebral zone — report significant improvement in ocular appearance and self-confidence following surgery.</p><h3>Enables Subsequent Refractive or Cataract Surgery</h3><p>By removing the pterygium and allowing the cornea to stabilise, CLAL opens the door to accurate biometry for cataract surgery (intraocular lens calculation) or corneal topography-guided refractive procedures. Most surgeons recommend waiting 3–6 months post-excision before proceeding with LASIK or PRK to ensure the corneal shape has fully stabilised.</p>

<p>Pterygium surgery is generally safe, but as with any surgical procedure, complications can occur. CLAL carries specific additional risks related to the use of donor tissue.</p><h3>Graft Rejection</h3><p>Because CLAL uses allogeneic (donor) tissue, immune-mediated rejection is possible. The risk is estimated at 5–15% without adequate immunosuppression. Rejection typically presents as redness, injection around the graft, and graft oedema within weeks to months post-operatively. Prompt recognition and intensified topical corticosteroid therapy can usually reverse a rejection episode. To minimise this risk, some centres use HLA-matched cadaveric tissue or living-related donors; others use extended topical cyclosporine A prophylaxis for 6–12 months.</p><h3>Pterygium Recurrence</h3><p>Even with CLAL, recurrence rates of 3–10% are reported. Recurrence risk is higher in younger patients (under 40), those with aggressive vascularised pterygia, and those living in high-UV environments who do not use UV-protective eyewear post-operatively.</p><h3>Infection and Endophthalmitis</h3><p>Any intraocular or ocular surface procedure carries a risk of infection. Pterygium surgery is an external procedure and the risk of endophthalmitis (intraocular infection) is extremely rare. Wound infection at the graft site is more common but typically responds to topical antibiotic therapy.</p><h3>Scleral Thinning (Scleromalacia)</h3><p>This rare but serious complication is more commonly associated with adjuvant mitomycin-C use at higher concentrations. Scleral thinning can lead to scleral perforation in extreme cases and may require additional reconstructive surgery. The risk is minimised by careful MMC dosing and appropriate post-operative follow-up.</p><h3>Diplopia (Double Vision)</h3><p>The extraocular muscles (particularly the medial rectus) may be affected by the surgical dissection, leading to transient diplopia. This typically resolves within weeks but may occasionally be persistent.</p><h3>Over- or Under-Correction of Astigmatism</h3><p>Pterygium removal induces corneal topographic changes that can result in a shift in refractive error. Most patients experience improvement, but some develop new astigmatism related to the suture tension of the graft or altered healing. A final spectacle refraction should not be made until corneal topography has stabilised, typically 3–6 months post-operatively.</p><h3>Suture-Related Complications</h3><p>If sutures rather than fibrin glue are used, suture-related irritation, granuloma formation, or cheese-wiring through the graft can occur. Fibrin glue fixation has largely replaced sutures in experienced centres, with equivalent or better graft outcomes and faster patient rehabilitation.</p>

<p>Recovery after pterygium excision with CLAL is generally well-tolerated. Most patients experience moderate discomfort, redness, and watering for the first 1–2 weeks, managed with prescribed medications and lubricant drops.</p><h3>Immediate Post-Operative Period (Days 1–14)</h3><p>An eye pad or shield is worn for the first 24 hours. Post-operative medications typically include: <strong>topical antibiotic drops</strong> (e.g., moxifloxacin or chloramphenicol) four times daily for 2–4 weeks; <strong>topical corticosteroid drops</strong> (e.g., prednisolone acetate 1% or dexamethasone) to reduce inflammation and prevent rejection — frequency tapered over several weeks to months; <strong>lubricating eye drops</strong> (preservative-free artificial tears) frequently throughout the day to support surface healing. Patients should avoid rubbing the eye, swimming, dusty environments, and heavy exercise for the first 2–4 weeks. UV-protective sunglasses should be worn outdoors starting from day one and continued long-term to reduce recurrence risk.</p><h3>Clinic Follow-Up Schedule</h3><p>The standard follow-up schedule is: Day 1 (post-operative review), Day 7 (suture check if sutures used; wound inspection), Week 4 (assess graft take, taper steroids), Week 8 (refraction check, topography), Month 3 (assess recurrence, consider finalising spectacle prescription), Month 6 and 12 (long-term recurrence monitoring). Patients on topical cyclosporine for rejection prophylaxis may require visits at 3-month intervals throughout the first year.</p><h3>Immunosuppression Management</h3><p>The need for topical immunosuppressive therapy (cyclosporine 0.05–2% eye drops) distinguishes CLAL aftercare from conjunctival autograft management. Cyclosporine is typically used for 3–12 months depending on the centre protocol and the patient's rejection risk. Intraocular pressure must be monitored during prolonged corticosteroid use to identify steroid-responders at risk of ocular hypertension or glaucoma.</p><h3>Return to Normal Activities</h3><p>Most patients can return to desk work within 1–2 weeks. Driving is generally safe once visual acuity in the operated eye is adequate and discomfort minimal — typically by week 2. Heavy lifting, swimming, and contact sports should be avoided for 4–6 weeks. The operated eye may remain red and have visible sutures (if used) for 4–8 weeks.</p>

<p>The cost of pterygium excision with CLAL varies considerably based on surgical technique, facility type, donor tissue procurement, and geographic location.</p><h3>Estimated Costs by Region</h3><p><strong>United States:</strong> USD $2,500–$5,000 for the surgical procedure (surgeon + facility). Donor tissue procurement adds USD $500–$1,500 from an eye bank. Total with anaesthesia: USD $3,500–$7,000. Insurance (where applicable) may cover medically necessary pterygium surgery.</p><p><strong>United Kingdom:</strong> Available on the NHS for pterygia causing visual impairment or significant symptoms; private cost GBP £1,500–£3,500 including surgeon fee.</p><p><strong>India:</strong> INR 20,000–80,000 (approximately USD $250–$1,000) in top-tier hospitals for CLAL, inclusive of tissue. India is a leading medical tourism destination for this procedure due to highly experienced cornea specialists and eye banks.</p><p><strong>Singapore:</strong> SGD $3,000–$6,000 in private hospitals.</p><p><strong>Thailand / Malaysia:</strong> USD $1,000–$2,500 at accredited international hospitals in Bangkok, Kuala Lumpur, or Penang.</p><h3>Factors Driving Cost Variation</h3><ul><li><strong>Graft type:</strong> Cadaveric allograft tissue from an eye bank adds a tissue procurement cost not present with autograft. Living-related donor tissue requires an additional donor surgical procedure.</li><li><strong>Surgeon experience:</strong> Specialist cornea surgeons with high CLAL volume typically charge premium fees, but lower complication and recurrence rates justify this cost.</li><li><strong>Use of fibrin glue vs. sutures:</strong> Fibrin glue (TISSEEL) adds a modest material cost but reduces operative time and suture-related post-operative complications.</li><li><strong>Bilateral vs. unilateral:</strong> Surgery on both eyes increases total cost, though some facilities offer a reduced combined fee.</li><li><strong>Post-operative medications:</strong> Topical cyclosporine, steroids, and lubricants for 3–12 months add ongoing medication cost — budget USD $50–$150 per month.</li><li><strong>Use of adjuvant MMC:</strong> Minimal additional cost but requires careful post-operative monitoring.</li></ul><h3>Medical Tourism Considerations</h3><p>Patients from the USA, UK, and Australia frequently travel to India, Thailand, Singapore, or Spain for high-quality pterygium surgery at a fraction of domestic costs. The procedure requires only one day of surgery and approximately 1–2 follow-up visits over the subsequent 2–4 weeks, making it feasible for a short medical tourism visit. However, long-term follow-up (especially rejection monitoring for CLAL) is important, and arrangements for home-country follow-up ophthalmology must be made in advance.</p>

<p>Several alternative approaches exist for managing pterygium, ranging from conservative observation to different surgical graft techniques. The best choice depends on pterygium size, recurrence history, available conjunctival tissue, and patient-specific factors.</p><h3>Conservative Management (Observation and Symptom Control)</h3><p>Small, stable, asymptomatic pterygia that do not threaten vision can be monitored without surgery. Conservative measures include: <strong>UV-protective sunglasses</strong> (wrap-around lenses blocking 99–100% of UV-A and UV-B) to slow progression; <strong>lubricating eye drops</strong> (preservative-free artificial tears) to reduce surface irritation; <strong>topical anti-inflammatory drops</strong> (topical ketorolac or mild corticosteroid) for episodes of irritation and redness. Regular monitoring by an ophthalmologist every 6–12 months is appropriate.</p><h3>Conjunctival Autograft (CAG)</h3><p>For primary (first-time) pterygium surgery, conjunctival autograft using the patient's own superior bulbar conjunctiva is the gold standard. It avoids the graft rejection risk of CLAL, has equivalent recurrence rates (2–10%), and does not require post-operative immunosuppression. It is the preferred technique when sufficient healthy superior conjunctiva is available. CLAL becomes the preferred option only when autograft tissue is unavailable or insufficient.</p><h3>Amniotic Membrane Transplant (AMT)</h3><p>Cryopreserved human amniotic membrane (e.g., PROKERA) has anti-inflammatory and anti-fibrotic properties and is used as a graft material. It is particularly useful in eyes with significant ocular surface inflammation, scarring, or where conjunctival preservation is essential. Recurrence rates are somewhat higher than with CAG or CLAL (10–20%), but AMT is less immunogenic and requires less immunosuppression than CLAL.</p><h3>Bare Sclera Excision With Mitomycin-C (MMC)</h3><p>MMC is an antimetabolite that, when applied topically to the bare sclera at surgery, inhibits the fibrovascular proliferation that drives recurrence. While MMC-augmented bare sclera excision reduces recurrence rates compared to excision alone (to approximately 10–25%), it remains inferior to graft-based techniques and carries risks of scleral melt, avascular necrosis, and delayed wound healing. Its use is generally reserved as an adjuvant to graft surgery in high-risk cases, not as a standalone technique.</p><h3>Beta-Radiation Therapy</h3><p>Post-operative strontium-90 beta-radiation was historically used as an adjuvant to bare sclera excision to reduce recurrence. It is effective (recurrence rates 10–15%) but carries risks of scleral necrosis, dry eye, and cataract with cumulative radiation exposure. It is now rarely used in favour of safer graft techniques.</p>